Premium
Murine colon carcinoma cells engineered to produce human interleukin‐2 induce tumor‐specific anti‐tumor response
Author(s) -
Gunji Yoshio,
Tagawa Masatoshi,
Matsubara Hisahiro,
Takenaga Keizo,
Shimada Hideaki,
Kondo Fukuo,
Suzuki Takao,
Nakajima Kazuaki,
Aoki Taito,
Asano Takehide,
Ochiai Takenori,
Isono Kaichi,
Kageyama Hajime,
Nakamura Yohko,
Sakiyama Shigeru
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19960328)66:1<135::aid-ijc23>3.0.co;2-b
Subject(s) - fibrosarcoma , cytokine , biology , cancer research , carcinoma , pathology , immunology , medicine
Murine colon carcinoma cells (colon 26) transduced by a retrovirus vector with the human interleukin‐2 (IL‐2) cDNA were studied for their tumorigenicity. Although cell growth in vitro was not affected by integration of the IL‐2 gene, s.c. tumors of IL‐2‐producing colon 26 cells (H2) in syngeneic mice regressed spontaneously after producing small masses. Histological examination of the sites of tumor rejection revealed predominant infiltration of macrophages around the tumor necrotic mass. Subsequent challenge with parent colon 26 cells, but not with Meth A cells (fibrosarcoma of the same genetic background), did not result in tumor formation in mice which had been protected against H2 cells. Inoculation of H2 cells into syngeneic nude mice resulted in tumors with a retarded growth rate. Taken together, T cell‐dependent, tumor‐specific immunity is obtained by local IL‐2 secretion around colon tumors, and this experimental animal model gives us a clue(s) for investigating host anti‐tumor responses by cytokine production. © 1996 Wiley‐Liss, Inc.